1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

Biogen Leans On Plegridy To Help Extend The Life Of Avonex

 
• By Lisa LaMotta

The drug maker reports positive late-stage data for its newest multiple sclerosis product. The pegylated interferon could help its existing injectable interferon franchise maintain share against new oral options.

Most of the news coming out of Biogen Inc.these days is about Tecfidera (dimethyl fumarate), the highly anticipated, oral multiple sclerosis drug that is expected to get a green light from FDA by the end of the month. But the drug maker also is looking to maintain sales of its more mature MS franchise, Avonex (interferon beta-1a), amid increased competition in the therapeutic area. Despite the availability of several new drugs for MS, including some oral options, interferons are expected to remain a backbone of care, at least in the near-term.

Biogen is hoping to launch a new pegylated version of interferon beta-1a in 2014. The company expects to submit an NDA for the new product under the brand name Plegridy (peginterferon beta-1a) by mid-2013, based on positive Phase III data

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

UK MHRA’s Clinical Trial Lead On Combined Reviews, The Notification Scheme & Increasing Diversity

 
• By Eliza Slawther

In light of the UK’s MHRA announcing a major overhaul of its clinical trial legislation, the agency’s deputy director for clinical investigations and trials Andrea Manfrin tells the Pink Sheet what sponsors can expect from the new regulation.

US FDA COVID-19 Booster Strategy May Not Be As Controversial As It Seems

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s call for placebo-controlled trials to confirm the efficacy of COVID-19 boosters is drawing a lot of criticism, but former Commissioner Robert Califf also supported the idea.

EU Shaping Biotech Act To Unleash SME Potential

 
• By Neena Brizmohun

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.